La Jolla Pharma (LJPC) 13.81 $LJPC
La Jolla Pharmaceutical Company and the George Washington University Announce Exclusive Worldwide License Agreement
Business Wire - Tue Dec 09, 3:01PM CST
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, and the George Washington University (GW), today announced that La Jolla and GW have entered into an exclusive worldwide license agreement for GW intellectual property rights covering the use of angiotensin II for the therapeutic treatment of patients with hypotension and shock. La Jolla plans to initiate a phase 3 registration program of LJPC-501, La Jolla's proprietary formulation of angiotensin II, in catecholamine-resistant hypotension (CRH) in the first quarter of 2015.
LJPC: 13.81 (+0.76)
LaJolla down on clinical trial results
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:10PM CST
LJPC: 13.81 (+0.76)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 11:48AM CST
IMDZ: 22.35 (-0.20), VTNR: 3.21 (-0.03), CYBR: 37.98 (+0.13), LJPC: 13.81 (+0.76), ZAZA: 1.46 (-0.13), XPLR: 6.30 (-0.10), FUEL: 14.85 (+0.89), NADL: 1.47 (-0.09), DWA: 21.75 (+0.04), CZR: 12.83 (-2.03), RCAP: 11.81 (-0.10), AMTX: 4.33 (+0.04), FLML: 16.83 (+0.28), AMOT: 20.77 (-1.16), RVNC: 17.45 (-0.23), LOCM: 1.18 (-0.08), JGW: 8.68 (-0.32), ICLD: 3.01 (-0.05), VPCO: 1.31 (+0.04), CSH: 21.11 (+0.04)
La Jolla Pharma -12.5% AH after Q3 report, Phase 2 study results
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 5:00PM CST
LJPC: 13.81 (+0.76)
La Jolla Pharmaceutical posts 3Q loss
Automated Insights - Wed Nov 12, 4:06PM CST
SAN DIEGO (AP) _ La Jolla Pharmaceutical Co. (LJPC) on Wednesday reported a loss of $5.1 million, or 37 cents per share, in its third quarter.
LJPC: 13.81 (+0.76)
La Jolla Pharmaceutical misses by $0.06
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:39PM CST
LJPC: 13.81 (+0.76)
Results from Phase 2 Study of GCS-100 in Chronic Kidney Disease Being Presented at American Society of Nephrology Kidney Week
Business Wire - Wed Nov 12, 3:14PM CST
--Improvement More Pronounced in Diabetic Patients
LJPC: 13.81 (+0.76)
La Jolla Pharmaceutical Company Announces Third Quarter and Year-to-Date 2014 Financial Results and Corporate Highlights
Business Wire - Wed Nov 12, 3:02PM CST
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported third quarter and year-to-date 2014 financial results and highlighted recent corporate progress and near-term milestones.
LJPC: 13.81 (+0.76)
La Jolla Pharmaceutical (LJPC) in Focus: Stock Surges 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:44AM CST
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares surge over 10% on the day
ENDP: 68.77 (-2.45), LCI: 43.58 (-0.46), BCRX: 10.06 (+0.02), LJPC: 13.81 (+0.76)
La Jolla Pharmaceutical Co. (LJPC) Jumps: Stock Rises 10.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 8:32AM CDT
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares rise more than 10% on the day.
LJPC: 13.81 (+0.76), CEMP: 19.00 (+0.47), IG: 8.78 (+0.12), BIOD: 1.38 (-0.03)
5 Stocks Spiking on Unusual Volume
at The Street - Mon Oct 27, 6:00AM CDT
Keep these stocks trading on unusual volume on your trading radar.
SUSP: 46.00 (+0.69), LJPC: 13.81 (+0.76), IPCM: 43.63 (-0.18), EGBN: 34.19 (-0.88), CSL: 86.01 (-0.84)
La Jolla Pharmaceutical Company Announces Data Presentation at the American Society of Nephrology Kidney Week
Business Wire - Thu Oct 23, 3:01PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) ("the Company" or "La Jolla"
, a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that an abstract of the results for the Company's Phase 2 clinical trial of GCS-100 in chronic kidney disease (CKD) has been selected by the American Society of Nephrology's (ASN) Program Committee for poster presentation at the Kidney Week Annual Meeting. Kidney Week will be held November 11-16, 2014 in Philadelphia, Pennsylvania.
LJPC: 13.81 (+0.76)
La Jolla (LJPC) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 9:41AM CDT
La Jolla (LJPC) Shares March Higher, Can It Continue?
LJPC: 13.81 (+0.76)
La Jolla (LJPC) is Oversold: Can It Recover? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 10:43AM CDT
La Jolla (LJPC) is Oversold: Can It Recover?
LJPC: 13.81 (+0.76)
La Jolla Pharmaceutical Company to Provide Corporate Overview at the Rodman & Renshaw 16th Annual Global Investment Conference
Business Wire - Mon Sep 08, 7:01AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla" , a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Rodman & Renshaw 16th Annual Global Investment Conference taking place September 8-10 in New York City.
LJPC: 13.81 (+0.76)
La Jolla Pharmaceutical Company Announces First Patient Enrolled in Clinical Trial of LJPC-501 in Hepatorenal Syndrome
Business Wire - Mon Aug 25, 7:04AM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the first patient has been enrolled in the Phase 1/2 clinical trial of LJPC-501 for the treatment of type 1 and type 2 hepatorenal syndrome (HRS). HRS is a life-threatening form of progressive renal failure in patients with liver cirrhosis or fulminant liver failure.
LJPC: 13.81 (+0.76)
La Jolla Pharmaceutical Company Announces Second Quarter and Year-to-Date 2014 Financial Results
Business Wire - Thu Aug 14, 3:30PM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported second quarter and year-to-date 2014 financial results and highlighted recent corporate progress.
LJPC: 13.81 (+0.76)
La Jolla Pharmaceutical Company Receives Notice of Allowance for Additional Patent Claims Covering Modified Pectin for the Treatment of Chronic Inflammation
Business Wire - Thu Aug 14, 7:00AM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla" , a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the United States Patent and Trademark Office ("USPTO" has issued a notice of allowance for patent application number 14/254,510 covering methods of treating chronic inflammation by intravenous administration of aqueous modified pectin solutions with molecular weights greater than 25 kilodaltons.
LJPC: 13.81 (+0.76)
Is ViaSat (VSAT) Poised to Surprise Q1 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 11:50AM CDT
Satellite communications company ViaSat Inc. (VSAT), is set to release its first-quarter fiscal 2015 financial numbers after the closing bell on Aug 12, 2014.
CPG: 18.81 (-0.51), LJPC: 13.81 (+0.76), JCP: 6.38 (+0.29), VSAT: 62.66 (-0.88)
La Jolla Pharmaceutical Company to Provide Corporate Overview at the 2014 Wedbush Securities Life Sciences Conference
Business Wire - Mon Aug 11, 7:01AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla" , a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, will provide a corporate overview at the 2014 Wedbush Securities Life Sciences Conference taking place August 12-13 in New York City.
LJPC: 13.81 (+0.76)
La Jolla Pharmaceutical Company and the George Washington University Announce Exclusive Worldwide License Agreement
Business Wire - Tue Dec 09, 3:01PM CST
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, and the George Washington University (GW), today announced that La Jolla and GW have entered into an exclusive worldwide license agreement for GW intellectual property rights covering the use of angiotensin II for the therapeutic treatment of patients with hypotension and shock. La Jolla plans to initiate a phase 3 registration program of LJPC-501, La Jolla's proprietary formulation of angiotensin II, in catecholamine-resistant hypotension (CRH) in the first quarter of 2015.
LJPC: 13.81 (+0.76)
LaJolla down on clinical trial results
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:10PM CST
LJPC: 13.81 (+0.76)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 11:48AM CST
IMDZ: 22.35 (-0.20), VTNR: 3.21 (-0.03), CYBR: 37.98 (+0.13), LJPC: 13.81 (+0.76), ZAZA: 1.46 (-0.13), XPLR: 6.30 (-0.10), FUEL: 14.85 (+0.89), NADL: 1.47 (-0.09), DWA: 21.75 (+0.04), CZR: 12.83 (-2.03), RCAP: 11.81 (-0.10), AMTX: 4.33 (+0.04), FLML: 16.83 (+0.28), AMOT: 20.77 (-1.16), RVNC: 17.45 (-0.23), LOCM: 1.18 (-0.08), JGW: 8.68 (-0.32), ICLD: 3.01 (-0.05), VPCO: 1.31 (+0.04), CSH: 21.11 (+0.04)
La Jolla Pharma -12.5% AH after Q3 report, Phase 2 study results
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 5:00PM CST
LJPC: 13.81 (+0.76)
La Jolla Pharmaceutical posts 3Q loss
Automated Insights - Wed Nov 12, 4:06PM CST
SAN DIEGO (AP) _ La Jolla Pharmaceutical Co. (LJPC) on Wednesday reported a loss of $5.1 million, or 37 cents per share, in its third quarter.
LJPC: 13.81 (+0.76)
La Jolla Pharmaceutical misses by $0.06
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:39PM CST
LJPC: 13.81 (+0.76)
Results from Phase 2 Study of GCS-100 in Chronic Kidney Disease Being Presented at American Society of Nephrology Kidney Week
Business Wire - Wed Nov 12, 3:14PM CST
--Improvement More Pronounced in Diabetic Patients
LJPC: 13.81 (+0.76)
La Jolla Pharmaceutical Company Announces Third Quarter and Year-to-Date 2014 Financial Results and Corporate Highlights
Business Wire - Wed Nov 12, 3:02PM CST
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported third quarter and year-to-date 2014 financial results and highlighted recent corporate progress and near-term milestones.
LJPC: 13.81 (+0.76)
La Jolla Pharmaceutical (LJPC) in Focus: Stock Surges 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:44AM CST
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares surge over 10% on the day
ENDP: 68.77 (-2.45), LCI: 43.58 (-0.46), BCRX: 10.06 (+0.02), LJPC: 13.81 (+0.76)
La Jolla Pharmaceutical Co. (LJPC) Jumps: Stock Rises 10.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 8:32AM CDT
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares rise more than 10% on the day.
LJPC: 13.81 (+0.76), CEMP: 19.00 (+0.47), IG: 8.78 (+0.12), BIOD: 1.38 (-0.03)
5 Stocks Spiking on Unusual Volume
at The Street - Mon Oct 27, 6:00AM CDT
Keep these stocks trading on unusual volume on your trading radar.
SUSP: 46.00 (+0.69), LJPC: 13.81 (+0.76), IPCM: 43.63 (-0.18), EGBN: 34.19 (-0.88), CSL: 86.01 (-0.84)
La Jolla Pharmaceutical Company Announces Data Presentation at the American Society of Nephrology Kidney Week
Business Wire - Thu Oct 23, 3:01PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) ("the Company" or "La Jolla"
, a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that an abstract of the results for the Company's Phase 2 clinical trial of GCS-100 in chronic kidney disease (CKD) has been selected by the American Society of Nephrology's (ASN) Program Committee for poster presentation at the Kidney Week Annual Meeting. Kidney Week will be held November 11-16, 2014 in Philadelphia, Pennsylvania. LJPC: 13.81 (+0.76)
La Jolla (LJPC) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 9:41AM CDT
La Jolla (LJPC) Shares March Higher, Can It Continue?
LJPC: 13.81 (+0.76)
La Jolla (LJPC) is Oversold: Can It Recover? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 10:43AM CDT
La Jolla (LJPC) is Oversold: Can It Recover?
LJPC: 13.81 (+0.76)
La Jolla Pharmaceutical Company to Provide Corporate Overview at the Rodman & Renshaw 16th Annual Global Investment Conference
Business Wire - Mon Sep 08, 7:01AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"
, a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Rodman & Renshaw 16th Annual Global Investment Conference taking place September 8-10 in New York City. LJPC: 13.81 (+0.76)
La Jolla Pharmaceutical Company Announces First Patient Enrolled in Clinical Trial of LJPC-501 in Hepatorenal Syndrome
Business Wire - Mon Aug 25, 7:04AM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the first patient has been enrolled in the Phase 1/2 clinical trial of LJPC-501 for the treatment of type 1 and type 2 hepatorenal syndrome (HRS). HRS is a life-threatening form of progressive renal failure in patients with liver cirrhosis or fulminant liver failure.
LJPC: 13.81 (+0.76)
La Jolla Pharmaceutical Company Announces Second Quarter and Year-to-Date 2014 Financial Results
Business Wire - Thu Aug 14, 3:30PM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported second quarter and year-to-date 2014 financial results and highlighted recent corporate progress.
LJPC: 13.81 (+0.76)
La Jolla Pharmaceutical Company Receives Notice of Allowance for Additional Patent Claims Covering Modified Pectin for the Treatment of Chronic Inflammation
Business Wire - Thu Aug 14, 7:00AM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla"
, a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the United States Patent and Trademark Office ("USPTO" has issued a notice of allowance for patent application number 14/254,510 covering methods of treating chronic inflammation by intravenous administration of aqueous modified pectin solutions with molecular weights greater than 25 kilodaltons. LJPC: 13.81 (+0.76)
Is ViaSat (VSAT) Poised to Surprise Q1 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 11:50AM CDT
Satellite communications company ViaSat Inc. (VSAT), is set to release its first-quarter fiscal 2015 financial numbers after the closing bell on Aug 12, 2014.
CPG: 18.81 (-0.51), LJPC: 13.81 (+0.76), JCP: 6.38 (+0.29), VSAT: 62.66 (-0.88)
La Jolla Pharmaceutical Company to Provide Corporate Overview at the 2014 Wedbush Securities Life Sciences Conference
Business Wire - Mon Aug 11, 7:01AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"
, a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, will provide a corporate overview at the 2014 Wedbush Securities Life Sciences Conference taking place August 12-13 in New York City. LJPC: 13.81 (+0.76)
